Program
OPC 131461
A development code. Also written as “OPC-131461”, “OPC 131461 10mg group” and “OPC 131461 5mg group”.
Its studies are mostly in Heart Failure, led by Otsuka.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 20 open or running | phase 2since Nov 7, 2022 | Nov 7, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2022First study: phase 2 study in Edema, CardiacFirst studyNCT05615363 · 157 enrolled · Japan
- Jan 22, 2025Phase 2 study in Heart FailureNCT06795399
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06795399Heart Failure | 2 | Withdrawn | May 25, 2025 | 0 |
| NCT05615363Edema, Cardiac · Japan | 2 | Completed | Oct 21, 2024 | 157 |
How it is read
Names in the registry
- “OPC-131461”, 1 entry
- “OPC 131461 10mg group”, 1 entry
- “OPC 131461 5mg group”, 1 entry
- “OPC 131461 2mg group”, 1 entry
- “OPC 131461 1mg group”, 1 entry
Codes read as this program: OPC131461.
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.